Parent Toddler Obesity Study (PTOS)
试验速览
- 阶段
- 4 期
- 状态
- 撤回
- 入组人数
- 50
- 试验地点
- 2
- 主要终点
- Change in Toddler's Body Mass index (BMI) percentile at week 37
研究概览
简要总结
The purpose of this study is to treat toddler obesity by improving the toddler nutritional environment. Parents will participate in a free internet nutrition program and may also take obesity medication. These measures may improve the parental nutritional environment and in turn, improve the toddler nutritional environment as well.
详细描述
Fifty parent or caregiver and toddler teams will be enrolled in a 37 week study in which the parents or caregivers will be randomized to receive either an obesity drug or a placebo, while simultaneously enrolled in the Full Plate Living lifestyle program. Study eligibility and ongoing participation will be assessed by lab results, biometric measurements and nutrition questionnaires to monitor the impact of diet and medication on the parental dietary environment. Toddler body mass index (BMI) will be calculated at study inception and completion to assess potential impact on the toddler dietary environment. Teaching will be provided to parents on healthy dietary choices, adequate sleep and stress control.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 12 Months 至 75 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Self-identify as being of Hispanic/Latino or African American ethnicity
- •BMI ≥30 with a stable weight (no more than 5% variation during the previous 3 months) and an agreement not to initiate any other weight loss
- •HbAlc ≤ 6.4
- •Fluent in written and spoken English
排除标准
- •Current cancer treatment
- •Have been treated with prescription drugs that promote weight loss (for example, liraglutide [Saxenda™], orlistat [Xenical®], phentermine Adipex®], phentermine/topiramate [Qsymia™], semaglutide 2.4 mg [Wegovy™], tirzepatide [Zepbound™], bupropion/naltrexone [Contrave™], phentermine [Lomaira™] or similar other weight loss medications including over-the-counter (OTC) medications (for example, Alli®). Use of obesogenic medications (including but not limited to steroids, haloperidol, clozapine, risperidone, olanzapine, amitriptyline, imipramine, paroxetine, and lithium) which cannot be substituted or stopped
- •History of drug or alcohol abuse
- •Nursing or planning to become pregnant in the next 10 months
- •Unwilling to use accepted standards of birth control if female and before menopause age. (i.e. IUD, birth control pills/injections, tubal or vas deferens ligation) during the study and for 30 days after the study is completed. Condoms or rhythm methods are not sufficient.
- •Inclusion Criteria: (Toddler)
- •Self-identify as being of Hispanic/Latino or African American ethnicity
- •BMI ≥ 95th percentile for age, gender and height
- •Age 12 to 36 months of age
- •Spends at least half of its awake time per day with the P/OCG who is the consenting adult and who provides at least half of the toddler's diet on that day
- •Exclusion Criteria (Toddler)
- •Current cancer treatment
- •Use of obesogenic medications (including but not limited to steroids, haloperidol, clozapine, risperidone, olanzapine, amitriptyline, imipramine, paroxetine, and lithium) which cannot be substituted or stopped
- •Genetic disorders and/or physical or mental handicaps that would limit participation in the study and/or the lifestyle intervention
- •Any special dietary or exercise requirements
- •Any established chromosome abnormalities that might be associated with obesity
研究组 & 干预措施
Active Lomaira
Participants will receive Lomaira 8mg for 12 weeks and off 12 weeks, will restart at week 24 for 12 weeks one tablet per day 30 minutes before a meal.
干预措施: Lomaira 8Mg Tablet (Drug)
结局指标
主要结局
Change in Toddler's Body Mass index (BMI) percentile at week 37
时间窗: Change between baseline visit and final study visit at week 37
Toddler BMI will be measured at enrollment and at final study visit week 37. BMI will be calculated using the InBody Scale. This is a composite measurement consisting of height and weight.
Change in parent's Body Mass index (BMI) at week 37
时间窗: Change between baseline visit and final study visit at week 37
Adults BMI will be measured at enrollment and at final study visit week 37. BMI will be calculated using the InBody Scale. This is a composite measurement consisting of height and weight.
次要结局
未报告次要终点